DK2966175T3 - Farmaceutiske sammensætninger indeholdende cortexolon-17-alpha-propionat - Google Patents

Farmaceutiske sammensætninger indeholdende cortexolon-17-alpha-propionat Download PDF

Info

Publication number: DK2966175T3
Authority: DK; Denmark
Prior art keywords: cortexolon; propionate; alpha; pharmaceutical compositions; compositions containing
Prior art date: 2007-08-03

Application number

DK15175112.0T

Other languages

English (en)

Inventor

Mauro Ajani

Luigi Moro

Original Assignee

Cassiopea S P A

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-08-03

Filing date

2008-07-24

Publication date

2019-07-01

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40278805&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2966175(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-07-24 Application filed by Cassiopea S P A filed Critical Cassiopea S P A

2019-07-01 Application granted granted Critical

2019-07-01 Publication of DK2966175T3 publication Critical patent/DK2966175T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
- C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
- C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P33/00—Preparation of steroids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P33/00—Preparation of steroids
- C12P33/005—Degradation of the lateral chains at position 17

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Dermatology (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Biochemistry (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Reproductive Health (AREA)
Urology & Nephrology (AREA)
Molecular Biology (AREA)
Microbiology (AREA)
General Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Steroid Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Crystals, And After-Treatments Of Crystals (AREA)

DK15175112.0T 2007-08-03 2008-07-24 Farmaceutiske sammensætninger indeholdende cortexolon-17-alpha-propionat DK2966175T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IT001616A ITMI20071616A1 (it)	2007-08-03	2007-08-03	Processo enzimatico per l'ottenimento di 17-alfa monoesteri del cortexolone e/o suoi 9,11-deidroderivati.
EP12173152.5A EP2503004B1 (en)	2007-08-03	2008-07-24	Cortexolone-17alpha-propionate in crystalline form I

Publications (1)

Publication Number	Publication Date
DK2966175T3 true DK2966175T3 (da)	2019-07-01

Family

ID=40278805

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
DK15175112.0T DK2966175T3 (da)	2007-08-03	2008-07-24	Farmaceutiske sammensætninger indeholdende cortexolon-17-alpha-propionat
DK12173152.5T DK2503004T3 (da)	2007-08-03	2008-07-24	Cortexolon-17alfa-propionat i krystallinsk form I
DK08775319.0T DK2173891T3 (da)	2007-08-03	2008-07-24	Enzymatisk fremgangsmåde for at opnå cortexolon-17-alfa-propionat i krystallinsk form III
DK12173228.3T DK2503005T3 (da)	2007-08-03	2008-07-24	Cortexolon-17alfa-propionat i krystallinsk hydratform IV

Family Applications After (3)

Application Number	Title	Priority Date	Filing Date
DK12173152.5T DK2503004T3 (da)	2007-08-03	2008-07-24	Cortexolon-17alfa-propionat i krystallinsk form I
DK08775319.0T DK2173891T3 (da)	2007-08-03	2008-07-24	Enzymatisk fremgangsmåde for at opnå cortexolon-17-alfa-propionat i krystallinsk form III
DK12173228.3T DK2503005T3 (da)	2007-08-03	2008-07-24	Cortexolon-17alfa-propionat i krystallinsk hydratform IV

Country Status (25)

Country	Link
US (9)	US8785427B2 (da)
EP (5)	EP2173891B1 (da)
JP (3)	JP5646992B2 (da)
KR (1)	KR101495192B1 (da)
CN (3)	CN104861023B (da)
AR (3)	AR072235A1 (da)
AU (1)	AU2008285784B2 (da)
BR (1)	BRPI0814163A2 (da)
CA (3)	CA2691445C (da)
DK (4)	DK2966175T3 (da)
ES (4)	ES2551910T3 (da)
HR (4)	HRP20140421T1 (da)
HU (3)	HUE026507T2 (da)
IT (1)	ITMI20071616A1 (da)
LT (1)	LT2966175T (da)
MX (4)	MX363238B (da)
NZ (3)	NZ599437A (da)
PL (4)	PL2503004T3 (da)
PT (4)	PT2503004E (da)
RS (4)	RS58950B1 (da)
RU (2)	RU2482190C2 (da)
SI (4)	SI2503004T1 (da)
TR (1)	TR201909129T4 (da)
WO (1)	WO2009019138A2 (da)
ZA (2)	ZA201000587B (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ITMI20071616A1 (it) *	2007-08-03	2009-02-04	Cosmo Spa	Processo enzimatico per l'ottenimento di 17-alfa monoesteri del cortexolone e/o suoi 9,11-deidroderivati.
ITMI20132157A1 (it)	2013-12-20	2015-06-21	Cosmo Dermatos Srl	Cortexolone 17alfa-propionate for use in the treatment of skin wounds and/or atrophic skin disorders . cortexolone 17alfa-propionato per uso nel trattamento delle ferite della pelle e/o disordini atrofici della pelle.
EP3006453A1 (en) *	2014-10-08	2016-04-13	Cosmo Technologies Ltd.	17alpha-monoesters and 17alpha,21-diesters of cortexolone for use in the treatment of tumors
EP3108879A1 (en)	2015-06-25	2016-12-28	Cassiopea S.p.A.	High concentration formulation
CN112028956A (zh) *	2020-09-10	2020-12-04	那路新	合成21-羟基-17-(1-氧代丙氧基)孕甾-4-烯-3,20-二酮的方法
US20240018181A1 (en)	2020-10-19	2024-01-18	Industriale Chimica S.R.L.	Process for the production of 21-(acetyloxy)-17-(propionyloxy)-pregn-4-ene-3,20-dione
IT202100008429A1 (it)	2021-04-06	2022-10-06	Farmabios Spa	Processo per la preparazione di cortexolone 17α-propionato e sua nuova forma cristallina idrata
CN114410727B (zh) *	2022-01-25	2023-09-19	山东诺明康药物研究院有限公司	一种克拉考特酮的制备方法
CN115073546A (zh) *	2022-06-01	2022-09-20	浙江神洲药业有限公司	一种新型雄激素受体抑制剂的制备方法
CN115466301A (zh) *	2022-08-29	2022-12-13	扬州奥锐特药业有限公司	一种甾体化合物，其晶型a及它们的制备方法和用途
IT202300001929A1 (it)	2023-02-07	2024-08-07	Farmabios Spa	Cocristalli di cortexolone 17-propionato e metodi per la loro preparazione
TW202444338A (zh)	2023-04-07	2024-11-16	義大利商卡斯歐皮亞股份公司	克拉司酮與米諾地爾之組合療法
EP4529925A1 (en)	2023-09-26	2025-04-02	Cassiopea S.p.A.	Cortexolone-17-alpha- propionate for treating acneiform eruptions
TW202519237A (zh)	2023-09-26	2025-05-16	義大利商卡斯歐皮亞股份公司	用於治療痤瘡樣疹之皮甾酮-17α-丙酸酯
WO2025094021A1 (en) *	2023-10-31	2025-05-08	Lupin Limited	Stable topical cream formulation of clascoterone
WO2025125508A1 (en)	2023-12-14	2025-06-19	Cassiopea S.P.A.	Cortexolone-17αlpha-propionate combinations for treating acne
WO2025149998A1 (en)	2024-01-11	2025-07-17	Glenmark Specialty S.A.	Topical composition comprising clascoterone and latanoprost for alopecia
WO2025172818A1 (en)	2024-02-14	2025-08-21	Cassiopea S.P.A.	Pyrilutamide combination therapy

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB791771A (en)	1954-07-29	1958-03-12	Merck & Co Inc	Steroid compounds
US2985650A (en) *	1958-05-28	1961-05-23	Syntex Sa	6alpha-ammonio-derivatives of 11-keto cortical hormones
CH429716A (de) *	1961-06-24	1967-02-15	Vismara Francesco Spa	Verfahren zur Herstellung von 17a-Acyloxy-21-hydroxy-Steroiden
NL6605515A (da) *	1966-04-25	1967-10-26
NL6605514A (da) *	1966-04-25	1967-10-26
US3780177A (en) *	1967-06-16	1973-12-18	Warner Lambert Co	17-butyrate,21-ester derivatives of 6alpha,9alpha-difluoroprednisolone,compositions and use
US3733318A (en)	1972-03-23	1973-05-15	Syntex Corp	21-orthoesters of cortical steroids and methods of preparing same
JPS5910799B2 (ja) *	1975-07-15	1984-03-12	大正製薬株式会社	プレグナン系ステロイド１７−エステル類の製法
JPS6040439B2 (ja)	1978-03-29	1985-09-11	大正製薬株式会社	ヒドロコルチゾン誘導体
US4318853A (en)	1980-01-31	1982-03-09	The Upjohn Company	9β,11β-Epoxy-5β-corticoids
GB2109817B (en)	1981-11-18	1985-07-03	Ibm	Electrodeposition of chromium
DE3243482A1 (de) *	1982-11-22	1984-05-24	Schering AG, 1000 Berlin und 4709 Bergkamen	Neue 6(alpha)-methylkortikoide, ihre herstellung und verwendung
DE3402330A1 (de) *	1984-01-20	1985-07-25	Schering AG, 1000 Berlin und 4709 Bergkamen	1(alpha),2(alpha)-methylen-6-methylen- und 6(alpha)-methyl-pregnene, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
US4920216A (en)	1987-05-28	1990-04-24	The Trustees Of Columbia In The City Of New York	Selective chlorination of steroids and other substrates directed by covalently linked pyridine derivatives acting as templates
US5264428A (en) *	1990-02-16	1993-11-23	Kanoldt Arzneimittel Gmbh	Use of stigmasta-4-en-3-one in the treatment of androgen dependent diseases
JPH08135789A (ja)	1994-11-09	1996-05-31	Komatsu Ltd	車両の油圧式駆動装置の変速装置およびその変速制御方法
DE19653730C2 (de)	1996-12-11	1999-06-24	Schering Ag	Immobilisierte Proteine aus Rohextrakt und deren Verwendung zur Umsetzung von Estern
CN1090180C (zh)	1997-06-25	2002-09-04	帝人株式会社	维生素d3衍生物及其用于炎性呼吸道疾病的治疗剂
GEP20084399B (en)	2001-05-22	2008-06-10	Pfizer Prod Inc	Crystal forms of azithromycin
ITMI20011762A1 (it)	2001-08-10	2003-02-10	Cosmo Spa	Esteri di 17alfa,21-diidrossipregnene, loro uso come agenti anti-androgenetici e procedimenti per la loro preparazione
WO2004060347A2 (en)	2002-09-03	2004-07-22	Transform Pharmaceuticals, Inc.	Pharmaceutical propylene glycol solvate compositions
EP1491190A4 (en) *	2002-03-27	2006-01-04	Shionogi & Co	DECOMPOSITION INHIBITOR FOR CARTRIDGE EXTRACELLULAR MATRIX
ES2273061T3 (es) *	2002-08-02	2007-05-01	Schering Aktiengesellschaft	Agentes moduladores de receptores de progesterona con actividad antigonadotropa elevada para el control de fertilidad femenina y para la terapia por reemplazo hormonal.
US20040138187A1 (en)	2002-08-28	2004-07-15	Reading Christopher L.	Therapeutic treatment methods
US7169809B2 (en)	2003-03-05	2007-01-30	Merck Frosst Company	Nitric oxide releasing prodrugs of diaryl-2-(5H)-furanones as cyclooxygenase-2 inhibitors
US20050008704A1 (en)	2003-07-11	2005-01-13	Ray Anup Kumar	Pharmaceutical composition for solubility enhancement of hydrophobic drugs
JP2008189549A (ja)	2005-05-12	2008-08-21	Astellas Pharma Inc	カルボン酸誘導体またはその塩
PE20070343A1 (es) *	2005-07-29	2007-05-12	Medivir Ab	Inhibidores macrociclicos del virus de la hepatitis c
ITMI20051695A1 (it) *	2005-09-14	2007-03-15	Cosmo Spa	Uso di 17a-esteri c3-c10 del 9,11-deidrocortexolone cme agenti anti-gonadotropinici
ITMI20071616A1 (it) *	2007-08-03	2009-02-04	Cosmo Spa	Processo enzimatico per l'ottenimento di 17-alfa monoesteri del cortexolone e/o suoi 9,11-deidroderivati.
EP3178465A1 (en)	2010-12-06	2017-06-14	Follica, Inc.	Methods for treating baldness and promoting hair growth
ITMI20132157A1 (it)	2013-12-20	2015-06-21	Cosmo Dermatos Srl	Cortexolone 17alfa-propionate for use in the treatment of skin wounds and/or atrophic skin disorders . cortexolone 17alfa-propionato per uso nel trattamento delle ferite della pelle e/o disordini atrofici della pelle.
EP3108879A1 (en)	2015-06-25	2016-12-28	Cassiopea S.p.A.	High concentration formulation
JP2024106500A (ja)	2023-01-27	2024-08-08	理想科学工業株式会社	画像形成装置
JP2024161998A (ja)	2023-05-09	2024-11-21	トヨタ自動車株式会社	車載機

2007
- 2007-08-03 IT IT001616A patent/ITMI20071616A1/it unknown
2008
- 2008-07-18 AR ARP080103135A patent/AR072235A1/es unknown
- 2008-07-24 HU HUE12173228A patent/HUE026507T2/hu unknown
- 2008-07-24 RS RS20190782A patent/RS58950B1/sr unknown
- 2008-07-24 BR BRPI0814163-0A2A patent/BRPI0814163A2/pt not_active Application Discontinuation
- 2008-07-24 CA CA2691445A patent/CA2691445C/en not_active Expired - Fee Related
- 2008-07-24 NZ NZ599437A patent/NZ599437A/xx unknown
- 2008-07-24 MX MX2014009552A patent/MX363238B/es unknown
- 2008-07-24 WO PCT/EP2008/059702 patent/WO2009019138A2/en not_active Ceased
- 2008-07-24 PT PT121731525T patent/PT2503004E/pt unknown
- 2008-07-24 ES ES12173152.5T patent/ES2551910T3/es active Active
- 2008-07-24 PL PL12173152T patent/PL2503004T3/pl unknown
- 2008-07-24 DK DK15175112.0T patent/DK2966175T3/da active
- 2008-07-24 CN CN201510158436.8A patent/CN104861023B/zh active Active
- 2008-07-24 SI SI200831528T patent/SI2503004T1/sl unknown
- 2008-07-24 PL PL15175112T patent/PL2966175T3/pl unknown
- 2008-07-24 HU HUE12173152A patent/HUE026206T2/hu unknown
- 2008-07-24 PT PT121732283T patent/PT2503005E/pt unknown
- 2008-07-24 MX MX2010001256A patent/MX2010001256A/es active IP Right Grant
- 2008-07-24 EP EP08775319.0A patent/EP2173891B1/en active Active
- 2008-07-24 DK DK12173152.5T patent/DK2503004T3/da active
- 2008-07-24 US US12/671,932 patent/US8785427B2/en active Active
- 2008-07-24 RS RS20150691A patent/RS54354B1/sr unknown
- 2008-07-24 RS RS20150723A patent/RS54361B1/sr unknown
- 2008-07-24 DK DK08775319.0T patent/DK2173891T3/da active
- 2008-07-24 DK DK12173228.3T patent/DK2503005T3/da active
- 2008-07-24 ES ES15175112T patent/ES2732326T3/es active Active
- 2008-07-24 CA CA2871039A patent/CA2871039C/en not_active Expired - Fee Related
- 2008-07-24 SI SI200832066T patent/SI2966175T1/sl unknown
- 2008-07-24 NZ NZ61595308A patent/NZ615953A/en unknown
- 2008-07-24 EP EP19163462.5A patent/EP3521298A1/en active Pending
- 2008-07-24 EP EP12173152.5A patent/EP2503004B1/en active Active
- 2008-07-24 RU RU2010107599/10A patent/RU2482190C2/ru active
- 2008-07-24 HU HUE15175112 patent/HUE044237T2/hu unknown
- 2008-07-24 NZ NZ600767A patent/NZ600767A/xx unknown
- 2008-07-24 LT LTEP15175112.0T patent/LT2966175T/lt unknown
- 2008-07-24 ES ES08775319.0T patent/ES2462946T3/es active Active
- 2008-07-24 TR TR2019/09129T patent/TR201909129T4/tr unknown
- 2008-07-24 EP EP12173228.3A patent/EP2503005B1/en active Active
- 2008-07-24 PL PL12173228T patent/PL2503005T3/pl unknown
- 2008-07-24 AU AU2008285784A patent/AU2008285784B2/en active Active
- 2008-07-24 PT PT87753190T patent/PT2173891E/pt unknown
- 2008-07-24 SI SI200831538T patent/SI2503005T1/sl unknown
- 2008-07-24 CA CA2871025A patent/CA2871025C/en not_active Expired - Fee Related
- 2008-07-24 CN CN201310339201.XA patent/CN103450304B/zh active Active
- 2008-07-24 HR HRP20140421AT patent/HRP20140421T1/hr unknown
- 2008-07-24 SI SI200831199T patent/SI2173891T1/sl unknown
- 2008-07-24 JP JP2010518628A patent/JP5646992B2/ja active Active
- 2008-07-24 EP EP15175112.0A patent/EP2966175B1/en active Active
- 2008-07-24 PT PT15175112T patent/PT2966175T/pt unknown
- 2008-07-24 RS RS20140233A patent/RS53310B/sr unknown
- 2008-07-24 MX MX2014009553A patent/MX363701B/es unknown
- 2008-07-24 CN CN2008800245389A patent/CN101743316B/zh active Active
- 2008-07-24 ES ES12173228.3T patent/ES2554934T3/es active Active
- 2008-07-24 KR KR1020107003182A patent/KR101495192B1/ko active Active
- 2008-07-24 PL PL08775319T patent/PL2173891T3/pl unknown
2010
- 2010-01-26 ZA ZA2010/00587A patent/ZA201000587B/en unknown
- 2010-01-29 MX MX2019003639A patent/MX2019003639A/es active IP Right Grant
2011
- 2011-01-05 ZA ZA2011/00133A patent/ZA201100133B/en unknown
2012
- 2012-04-09 RU RU2012113839/10A patent/RU2599452C2/ru active
2013
- 2013-05-02 JP JP2013097009A patent/JP6108944B2/ja active Active
- 2013-11-07 US US14/073,928 patent/US9433628B2/en active Active
2015
- 2015-09-18 JP JP2015185882A patent/JP6174645B2/ja active Active
- 2015-10-19 US US14/886,774 patent/US9486458B2/en active Active
- 2015-11-03 HR HRP20151174TT patent/HRP20151174T1/hr unknown
- 2015-11-30 HR HRP20151298TT patent/HRP20151298T1/hr unknown
2016
- 2016-07-15 US US15/211,094 patent/US10159682B2/en active Active
- 2016-07-15 US US15/211,087 patent/US10166245B2/en active Active
2018
- 2018-04-03 AR ARP180100810A patent/AR111351A2/es unknown
- 2018-04-03 AR ARP180100811A patent/AR111202A2/es unknown
- 2018-11-19 US US16/195,083 patent/US10716796B2/en active Active
2019
- 2019-06-24 HR HRP20191143TT patent/HRP20191143T1/hr unknown
- 2019-11-18 US US16/686,738 patent/US11207332B2/en active Active
2021
- 2021-11-18 US US17/455,538 patent/US11938141B2/en active Active
2022
- 2022-11-18 US US18/057,031 patent/US12337002B2/en active Active

Also Published As

Publication number	Publication date
HUE026206T2 (hu)	2016-05-30
PT2173891E (pt)	2014-05-19
MX2019003639A (es)	2019-06-17
HUE044237T2 (hu)	2019-10-28
HRP20140421T1 (hr)	2014-06-06
AR072235A1 (es)	2010-08-18
AU2008285784B2 (en)	2014-06-26
RS54361B1 (sr)	2016-04-28
NZ600767A (en)	2013-11-29
ZA201000587B (en)	2011-04-28
CA2871039C (en)	2017-11-28
EP2503005A3 (en)	2012-10-03
AU2008285784A1 (en)	2009-02-12
US20160051566A1 (en)	2016-02-25
US10716796B2 (en)	2020-07-21
PL2173891T3 (pl)	2014-07-31
MX2010001256A (es)	2010-05-17
CA2691445A1 (en)	2009-02-12
LT2966175T (lt)	2019-08-26
EP2173891A2 (en)	2010-04-14
PL2503005T3 (pl)	2016-05-31
CA2871039A1 (en)	2009-02-12
WO2009019138A2 (en)	2009-02-12
PL2966175T3 (pl)	2019-11-29
KR101495192B1 (ko)	2015-02-25
TR201909129T4 (tr)	2019-07-22
HUE026507T2 (hu)	2016-06-28
DK2503005T3 (da)	2015-11-16
DK2503004T3 (da)	2015-11-02
US20200155572A1 (en)	2020-05-21
RU2010107599A (ru)	2011-09-10
US20190083511A1 (en)	2019-03-21
EP2503004B1 (en)	2015-09-02
PT2503004E (pt)	2015-12-09
HRP20191143T1 (hr)	2019-09-20
JP5646992B2 (ja)	2014-12-24
EP2966175B1 (en)	2019-05-08
CN101743316A (zh)	2010-06-16
PL2503004T3 (pl)	2016-05-31
AR111202A2 (es)	2019-06-12
US8785427B2 (en)	2014-07-22
CA2871025A1 (en)	2009-02-12
ES2554934T3 (es)	2015-12-28
JP2016014045A (ja)	2016-01-28
WO2009019138A3 (en)	2009-10-15
RU2012113839A (ru)	2013-10-20
US12337002B2 (en)	2025-06-24
CA2871025C (en)	2016-05-24
JP2013163683A (ja)	2013-08-22
EP2173891B1 (en)	2014-02-12
RS53310B (sr)	2014-10-31
US20110092472A1 (en)	2011-04-21
MX363238B (es)	2019-03-15
AR111351A2 (es)	2019-07-03
NZ615953A (en)	2015-03-27
KR20100044845A (ko)	2010-04-30
ITMI20071616A1 (it)	2009-02-04
US20140179654A1 (en)	2014-06-26
NZ599437A (en)	2013-11-29
US10159682B2 (en)	2018-12-25
JP2010535173A (ja)	2010-11-18
US11938141B2 (en)	2024-03-26
JP6108944B2 (ja)	2017-04-05
CA2691445C (en)	2017-11-28
US10166245B2 (en)	2019-01-01
RU2482190C2 (ru)	2013-05-20
US11207332B2 (en)	2021-12-28
HRP20151298T1 (hr)	2016-01-01
RS54354B1 (sr)	2016-04-28
CN103450304B (zh)	2016-05-25
JP6174645B2 (ja)	2017-08-02
EP2503005B1 (en)	2015-09-02
EP2503004A1 (en)	2012-09-26
ZA201100133B (en)	2014-03-26
PT2503005E (pt)	2015-12-09
BRPI0814163A2 (pt)	2015-01-20
RS58950B1 (sr)	2019-08-30
MX363701B (es)	2019-03-29
CN104861023B (zh)	2017-04-12
SI2503004T1 (sl)	2015-12-31
US20160326210A1 (en)	2016-11-10
SI2966175T1 (sl)	2019-08-30
EP2966175A1 (en)	2016-01-13
PT2966175T (pt)	2019-06-27
US9486458B2 (en)	2016-11-08
HRP20151174T1 (hr)	2015-12-04
CN103450304A (zh)	2013-12-18
DK2173891T3 (da)	2014-04-28
ES2551910T3 (es)	2015-11-24
CN104861023A (zh)	2015-08-26
EP2503005A2 (en)	2012-09-26
US20220280531A1 (en)	2022-09-08
EP3521298A1 (en)	2019-08-07
CN101743316B (zh)	2013-09-04
SI2503005T1 (sl)	2015-12-31
RU2599452C2 (ru)	2016-10-10
SI2173891T1 (sl)	2014-06-30
ES2732326T3 (es)	2019-11-21
US20160324873A1 (en)	2016-11-10
US9433628B2 (en)	2016-09-06
US20230104965A1 (en)	2023-04-06
ES2462946T3 (es)	2014-05-26

Publication	Publication Date	Title
LTPA2018005I1 (lt)	2018-02-12	Farmacinė kompozicija
LTPA2018014I1 (lt)	2018-12-10	Farmacinė kompozicija 514
RU2493831C3 (ru)	2017-06-08	Фармацевтические композиции
BRPI0721651A2 (pt)	2014-04-01	Composição farmacêutica
DK2966175T3 (da)	2019-07-01	Farmaceutiske sammensætninger indeholdende cortexolon-17-alpha-propionat
BRPI0715712A2 (pt)	2014-06-24	Composição farmacêutica
BRPI0719393A2 (pt)	2015-03-31	Composição farmacêutica
EP2191826A4 (en)	2010-09-15	PHARMACEUTICAL COMPOSITION
BRPI0820381A2 (pt)	2015-05-19	Formulações farmacêuticas
DK2079456T3 (da)	2013-03-18	Farmaceutiske cyclosporinsammensætninger
ME01423B (me)	2013-12-20	Fungicidni sastavi
DK2120884T3 (da)	2011-02-07	Farmaceutisk sammensætning
BRPI0716445A2 (pt)	2013-09-17	composiÇço farmacÊutica
BRPI0720234A2 (pt)	2013-12-24	Composição farmacêutica
DK2285413T3 (da)	2012-08-27	Farmaceutisk sammensætning
DK3300729T3 (da)	2020-01-20	Terapeutiske sammensætninger indeholdende macitentan
PT2209464E (pt)	2014-09-05	Composição farmacêutica antimalárica
EP2236149A4 (en)	2012-12-26	MEDICAL COMPOSITION
BRPI0921313A2 (pt)	2015-12-29	composição farmaucêutica
BRPI0820198A2 (pt)	2019-09-24	composições farmacêuticas
BRPI0912171A2 (pt)	2017-10-31	composição farmacêutica
ATE480227T1 (de)	2010-09-15	Pharmazeutische zusammensetzungen mit quetiapinfumarat
DK2271321T3 (da)	2012-08-27	Farmaceutisk sammensætning 271
EP2116241A4 (en)	2010-07-21	PHARMACEUTICAL COMPOSITION
BRPI0921301A2 (pt)	2015-12-29	composição farmacêutica